<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70304">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01654341</url>
  </required_header>
  <id_info>
    <org_study_id>MID-Frail</org_study_id>
    <secondary_id>278803-2</secondary_id>
    <nct_id>NCT01654341</nct_id>
  </id_info>
  <brief_title>Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes</brief_title>
  <acronym>MID-Frail</acronym>
  <official_title>A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN FRAIL AND PREFRAIL OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-Frail STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Diabetes for Older People</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio Madrileno de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bedfordshire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Igen Biotech SL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chu Hopitaux de Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hexabio Sarl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seconda Universita Degli Studi Di Napoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaet Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Gent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Univerzita Karlova v Praze</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio de Apoyo a la Investigacion Biomedica en Red</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Niche Science &amp; Technology Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Diabetes for Older People</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MID-Frail STUDY project focuses on the use of interventions designed to improve
      functional status and enhance quality of life (rather than traditional treatments such as
      glucose- and blood pressure- lowering) by acting on the mechanisms involved in producing
      frailty and its progression to adverse outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in summary ordinal score on the Short Physical Performance Battery test</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Short Physical Performance Battery (SPPB) is a simple test to measure lower extremity function using tasks that mimic daily activities. The SPPB examines 3 areas of lower extremity function; static balance, gait speed, and getting in and out of a chair. These areas represent essential tasks important for independent living and are thus an important outcome measure for patients with cardiovascular and pulmonary disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lawton IADL scale</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel ADL index</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-QoL index</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic costs/healthcare expenditure due to diabetes and its impact on disability and quality of life,</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Economic costs/healthcare expenditure due to diabetes and its impact on disability and quality of life, using an economic model embracing the direct health-related costs (in-patient, out-patient, pharmaceutical, etc), formal care costs (home care, respite care, day centers, etc) and the informal care costs (carer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hypoglycaemia</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Episodes of symptomatic hypoglycaemia (i.e., a recorded blood sugar less than 4 mmol/L, or symptoms or signs attributed to low blood sugar and responding to appropriate treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Episodes of hospital admission (i.e., any admission involving an overnight stay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of permanent institutionalization</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Episodes of permanent institutionalization (i.e., permanent move to any care setting other than the patient's own home, where paid staff are available to provide care if needed at any time during the day or night).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Strain Index</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Burden of the carer, as assessed by the modified Caregiver Strain Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1718</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects undergo usual standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with exercise, dietary and educational programs</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise, dietary and educational program</intervention_name>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant is willing and able to give written informed consent for participation in
             the study.

          -  Subjects aged 70 years or older, with a diagnosis of type 2 diabetes mellitus for at
             least 2 years.

          -  Require to fulfill Fried ÃÅs criteria for frail or pre-frail individuals.

        Exclusion criteria:

          -  Barthel score lower than 60 points.

          -  Inability to carry out SPPB test (total score=0).

          -  Mini Mental State Examination score less than 20 points.

          -  Subjects unwilling or unable to consent or unable to participate safely in
             intervention program.

          -  Previous history of myocardial infarction within 6 months, unstable angina or
             congestive heart failure in III-IV NYHA stage.

          -  Clinically instable patients in the clinical judgment of the investigator.

          -  Terminal illness (life expectancy &lt; 6 months).

          -  Any other condition that, in the clinical judgment of the investigator, means that it
             would not in the patient's best interests to enter the study.

          -  Current participation in clinical trial or any other investigational study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leocadio Rodr√≠guez Ma√±as, MD</last_name>
    <phone>00 34 916839360</phone>
    <phone_ext>6412</phone_ext>
    <email>lrodriguez.hugf@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bel√©n Riquelme</last_name>
    <email>briquelme.hugf@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <state>Getafe</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leocadio Rodr√≠guez Ma√±as, MD</last_name>
      <phone>00 34 916839360</phone>
      <phone_ext>6512</phone_ext>
      <email>lrodriguez.hugf@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Leocadio Rodr√≠guez Ma√±as, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 30, 2012</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
